Amryt Pharma says new cream delivers encouraging early results

02:32 EST 7 Jan 2019 | Proactive Investors

AP103 is a putative treatment for recessive dystrophic epidermolysis bullosa, a severe and very difficult to treat skin condition

Original Article: Amryt Pharma says new cream delivers encouraging early results

More From BioPortfolio on "Amryt Pharma says new cream delivers encouraging early results"